CN1907504A - Injectable hydrogel of sodium alginate crosslinked gelatin containing biphase calcium-phosphorus particles and preparation method and application thereof - Google Patents
Injectable hydrogel of sodium alginate crosslinked gelatin containing biphase calcium-phosphorus particles and preparation method and application thereof Download PDFInfo
- Publication number
- CN1907504A CN1907504A CN 200610036842 CN200610036842A CN1907504A CN 1907504 A CN1907504 A CN 1907504A CN 200610036842 CN200610036842 CN 200610036842 CN 200610036842 A CN200610036842 A CN 200610036842A CN 1907504 A CN1907504 A CN 1907504A
- Authority
- CN
- China
- Prior art keywords
- sodium alginate
- gelatin
- liquid
- biphase calcium
- calcium phosphor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010413 sodium alginate Nutrition 0.000 title claims abstract description 63
- 239000000661 sodium alginate Substances 0.000 title claims abstract description 63
- 229940005550 sodium alginate Drugs 0.000 title claims abstract description 63
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 108010010803 Gelatin Proteins 0.000 title claims abstract description 40
- 229920000159 gelatin Polymers 0.000 title claims abstract description 40
- 235000019322 gelatine Nutrition 0.000 title claims abstract description 40
- 235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 40
- 239000008273 gelatin Substances 0.000 title claims abstract description 38
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000017 hydrogel Substances 0.000 title abstract description 6
- 239000002245 particle Substances 0.000 title abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 44
- 239000000463 material Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 230000007547 defect Effects 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 37
- 239000008187 granular material Substances 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 28
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 24
- 238000002347 injection Methods 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 21
- 230000003647 oxidation Effects 0.000 claims description 20
- 238000007254 oxidation reaction Methods 0.000 claims description 20
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 19
- 238000004132 cross linking Methods 0.000 claims description 18
- 239000012153 distilled water Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000376 reactant Substances 0.000 claims description 10
- 239000012295 chemical reaction liquid Substances 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 229910021538 borax Inorganic materials 0.000 claims description 7
- 239000004328 sodium tetraborate Substances 0.000 claims description 7
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 7
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- SSVFMICWXDVRQN-UHFFFAOYSA-N ethanol;sodium Chemical compound [Na].CCO SSVFMICWXDVRQN-UHFFFAOYSA-N 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 3
- 239000000126 substance Substances 0.000 abstract description 11
- 239000003431 cross linking reagent Substances 0.000 abstract description 10
- 210000001519 tissue Anatomy 0.000 abstract description 9
- 231100000252 nontoxic Toxicity 0.000 abstract description 8
- 230000003000 nontoxic effect Effects 0.000 abstract description 8
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 229920005615 natural polymer Polymers 0.000 abstract description 3
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 abstract description 2
- 150000003384 small molecules Chemical class 0.000 abstract description 2
- 229920001744 Polyaldehyde Polymers 0.000 abstract 2
- 230000002051 biphasic effect Effects 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 12
- 229960000935 dehydrated alcohol Drugs 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 239000000499 gel Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 241000872931 Myoporum sandwicense Species 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 229910010272 inorganic material Inorganic materials 0.000 description 6
- 239000011147 inorganic material Substances 0.000 description 6
- 238000003760 magnetic stirring Methods 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 239000002639 bone cement Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- -1 polypropylene fumarate Polymers 0.000 description 4
- 229920001299 polypropylene fumarate Polymers 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000035126 Facies Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940078499 tricalcium phosphate Drugs 0.000 description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical group COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003462 bioceramic Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 229920000867 polyelectrolyte Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100032237 Dynein axonemal assembly factor 9 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000869152 Homo sapiens Dynein axonemal assembly factor 9 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229920001523 phosphate polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000011865 skeletal system disease Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种含双相钙磷颗粒的海藻酸钠交联明胶的可注射水凝胶，由多醛基海藻酸钠、明胶、双相钙磷颗粒为原料制备而成，其中各原料的重量配比为多醛基海藻酸钠5～20％、明胶10～30％、双相钙磷颗粒50～70％。本发明还公开了该可注射水凝胶的制备方法和应用。本发明提供的可注射水凝胶具有以下特点：(1)材料为安全无毒的纯天然聚合物体系，克服了以往材料中小分子交联剂的毒性和安全性问题；(2)为骨的再生和重建提供最佳的物理化学环境，使材料具有优异的生物相容性及可调的物理机械性能、生物降解性能；(3)材料可填充任何形状的骨缺损，能跟周围组织密切接触，易于操作、塑型方便、最大限度减少创伤，降低手术难度。The invention discloses an injectable hydrogel of sodium alginate cross-linked gelatin containing biphasic calcium-phosphorus particles, which is prepared from polyaldehyde-based sodium alginate, gelatin, and biphasic calcium-phosphorus particles as raw materials, wherein each raw material The weight ratio of the polyaldehyde sodium alginate is 5-20%, the gelatin is 10-30%, and the two-phase calcium phosphorus particles are 50-70%. The invention also discloses the preparation method and application of the injectable hydrogel. The injectable hydrogel provided by the present invention has the following characteristics: (1) the material is a safe and non-toxic pure natural polymer system, which overcomes the toxicity and safety problems of small molecule cross-linking agents in previous materials; Regeneration and reconstruction provide the best physical and chemical environment, so that the material has excellent biocompatibility, adjustable physical and mechanical properties, and biodegradability; (3) The material can fill any shape of bone defect and can be in close contact with the surrounding tissue , easy to operate, convenient to shape, minimize trauma and reduce operation difficulty.
Description
Technical field
The present invention relates to medical instruments field, be specifically related to a kind of injection aquagel material that comprises inorganic/organic facies, the invention still further relates to the preparation method and the application of this hydrogel material simultaneously.
Background technology
Damaged or the bone quantity not sufficient of bone is that prevalence is high, the serious threat health, reduce patient's's quality of life (can cause deformity) disease of skeletal system, and it can be caused by multiple diseases such as tumor, wound, severe infections, congenital malformations.Add up according to The World Health Organization (WHO): the chronic disease of half is all relevant with bone among the over-65s crowd; The fracture that causes along with osteoporosis is doubled and redoubled, nearly more than 40%50 years old the women will be affected.In the U.S., 6,500,000 fracture of having an appointment every year take place, and about 2,200,000 people need go the bone transplant operation.And in China, the not free patient of limbs reaches more than 1,500 ten thousand, and the damaged or bone injury patient of annual bone has more than 300 ten thousand.Along with the development of society and the aging of population, these numerals are also continuing rising, and global social economy is had an immense impact on.For causing people's attention, and be devoted to head it off, the United Nations, World Health Organization (WHO) and 38 countries unite and announce that 2000-2010 is bone and joint year.
The damaged traditional Therapeutic Method of bone is: from the implantation of artificial bone substitution material such as body, allosome or bone xenograft and multiple metal alloy, high molecular polymer, bioceramic.Though these methods have obtained some gratifying results, but still defectiveness, as limited from body bone source, moulding difficulty is transplanted the back for district's damage, and patient need accept two operations, stands very big pain, and there be may waiting of absorbing at a specified future date in bone graft; Allograph bone has antigenicity and pathophorous potential danger etc.; Artificial material exists not enough at aspects such as mechanical performance, biocompatibility, bone conductibility, therefore be badly in need of seeking new bone alternate material.
The damaged reparation of bone that appears as of organizational project has brought dawn, and it is used the principle and the method for life sciences and engineering and researchs and develops the biological substitution product, to repair or to rebuild the form and the function of damaged tissues and organ.It comprises three big key elements: three-dimensional porous rack, seed cell and bioactive molecule.The polymer support for preparing biodegradable and the good cell compatibility of tool has decisive significance to the successful structure of organizing.
Tissue engineering bracket has two kinds of forms, and a kind of is the preforming support, and a kind of is the injectable support.During application, the former needs seed cell is planted in the preforming support of external structure, replants after the new organization to be formed in patient's body, or earlier the preforming support is implanted, and allows patient's the autogenous cell stent-induced of growing into form new organization again; The latter then directly injects Injectable polymer (or suspension of polymer and other active ingredient) the interior damaged place of body and induces neoblastic formation.Therefore, the preforming support must be known size and the shape of intending filling damaged or cavity in advance, and this is very difficult for shape and the irregular damaged filling of size; And the implantation of complex needs surgical operation, and this also brings very big misery to patient.In addition, in the preforming support, the highly cross-linked plantation efficient of cell that causes of support is very low.The Injectable polymer support has then overcome above-mentioned shortcoming, the intervene operation of its available minimum is filled the cavity of Any shape and size, have that easy operating, plastotype are convenient, operating difficulty is low, operation wound is little, can reduce the advantage of patient's misery, risk of infection, cicatrization and medical expense to greatest extent.And owing to be liquid when not using, can follow the curing of reinjecting behind the uniform mixing such as competent cell, bioactive molecule, medicine.Therefore, from clinical viewpoint, the Injectable polymer support has tempting prospect, especially to bone growth promoting and soft tissue again.
The prerequisite characteristic of injectable materials that is used for organizational project is: 1. nontoxic; 2. excellent biological compatibility; 3. syringeability; 4. certain viscosity is to guarantee to stay the position that needs filling after the injection; 5. solidify rapidly and mild condition, should not heat release in the process or heat release less to avoid damaging surrounding tissue; 6. Shi Yi mechanical strength is with opposing original position pressure; 7. Shi Yi biodegradation rate is to adapt to the growth of tissue; 8. porous; 9. but binding bioactive molecule; 10. can sterilize with conventional method.
So far, the injectable materials that is used to bone tissue engineer comprises: 1. inorganic material, and as calcium phosphate bone cement and biphase calcium phosphor bioceramic etc., they have excellent biological compatibility, bone conductibility and certain osteoinductive; 2. organic material: comprise natural polymer and synthetic polymer.Natural polymer is generally all nontoxic, and hydrophilic, good biocompatibility have the cell recognition signal of some aminoacid sequence, be beneficial to cell adhesion, propagation and differentiation, but mechanical property can not be satisfied the demand, and needs to improve by modification, as sodium alginate, hyaluronic acid, collagen etc.Synthetic polymer can overcome the above-mentioned shortcoming of natural biologic material, and the micro structure of material and degradation time etc. can artificially be controlled, but disadvantage is to lack the cell recognition signal, be unfavorable for cell adhesion, can't provide the optimum chemical environment of osteanagenesis and reconstruction, as Polyethylene Glycol gel, polylactic acid, polyvinyl alcohol, polypropylene fumarate etc.General inorganic material rigidity and fragility are higher, are difficult to machine-shaping, and the conduction of barrier bone stress, are unfavorable for the generation and the reconstruction of new bone.The general elastic modelling quantity of Organic substance is higher, and warp resistance is not easily broken, but intensity is lower, in vivo easy deformation.For overcoming both shortcomings, researcher is they compound effects that reaches strengthening and toughening, with obtain to have excellent histocompatibility, the bone tissue engineering scaffold of favorable mechanical performance, controlled biological degradability.
Inorganic material is generally compound by two kinds of modes and organic material.A kind of is the physical mixed method: granular inorganic material and liquid organic material are mixed and made into paste injectable complex, by the self-curing formation solid tissue engineering rack of inorganic material.Rafal A.Mickiewicz etc. is mixed and made into calcium phosphate-polymer complex with several polyelectrolyte (polymine, polypropylene amine hydrochlorate), polyoxyethylene, bovine serum albumin solution (BSA) and commercially available self-curable calcium phosphate bone cement, to improve the comprcssive strength of support.The calcium phosphate bone cement that the compressive strength rate of compound polyelectrolyte is pure is big 6 times as a result.The comprcssive strength that contains 13-25% (wt%) BSA complex is 2 times of bone cement.They think that the increase of complex comprcssive strength gives the credit to polymer at a plurality of little intergranular bridging capabilities.The suspension (IBS) that O.Gauthier etc. form after with biphase calcium phosphor ceramic particle (BCP) and hydroxypropyl emthylcellulose aqueous solution, the pasty hydroxy apatite bone cement (CPC) of carbonation inject the terminal damaged place of new zealand rabbit femur respectively.After the result implanted for three weeks, the former is full of by new bone about 25% defective region, remaining pottery only is 19%～33% of a defective region, new bone bonds together biphase calcium phosphor granule, but the new bone of the latter is only in the CPC superficial growth, the new bone that forms only is full of 2.4% of defective region, and remaining CPC is 91% of a defective region.They think, because the CPC compact structure does not have obvious degradation again after the implantation, cell can not penetrate into CPC, therefore can't produce bone and substitute; And after the IBS system implant to solidify, BCP was suspended in the polymer solution, and the BCP granule is exposed in body fluid and the cell, and the IBS support degrades gradually, thus more morning, induce new bone formation more.But the resulting tissue scaffold design of this system still lacks enough intensity, so people attempt support with the Chemical Crosslinking Methods self-curing to improve the character of its mechanical performance and bone substituent.
Chemical crosslink technique is after organosilicon prepolymer aggressiveness, cross-linking agent and inorganic matter are mixed, and makes performed polymer be cross-linked to form embedding inorganic matter, combination is tightr, engineering properties is better three-dimensional netted complex by chemical crosslink reaction.Annalisa La Gatta etc. the acrylate-based poly-ε-lactide of low-molecular-weight terminal methyl (PCLf), light trigger and half-H 2 O calcium sulphate (CHS) are fully mixed (50/50, w/w) obtain the injectable bone tissue engineering bracket.As a result, CHS evenly is embedded in the PCL network, the system no cytotoxicity, and overcome the fragility of CHS and too fast absorption rate, improved its mechanical performance.Shulin He etc. are with polypropylene fumarate performed polymer (PPF), cross-linking agent two terminal methyl acrylate Polyethylene Glycol, initiator dibenzoyl peroxide/dichloromethane solution and liquid N, (β-TCP) (33wt%) behind mixing, forms the gel of chemical crosslinking rapidly in 8.0～2.6min for N-dimethyl-p-toluidines, bata-tricalcium phosphate granule.The adding of bata-tricalcium phosphate makes the comprcssive strength of complex increase to 58.4MPa.They think that this is biodegradable, the Injectable composite material of tool engineering machinery character can be used for plastic surgery's organizational project.Yaszenski MJ etc. implants rat tibia with PPF/ β-TCP composite behind disinfection by ultraviolet light damaged, can be observed material after 5 weeks and replaced by freshman bone tissue gradually.
Though chemical crosslink technique can make complex obtain excellent in mechanical properties, but still has defective.As using solvent, need use various initiators and cross-linking agent when crosslinked: as light trigger, metallic-ion crosslinking agent, covalent crosslinking agent (glutaraldehyde, carbodiimide etc.) for obtaining syringeability.Most of initiators, cross-linking agent and solvent tool height toxicity.In addition, the monomer of some synthetic polymer and catabolite also have cytotoxicity.The toxicity of raw material and catabolite makes these systems be difficult to be used as tissue engineering bracket, even because very the toxic agent of low concentration leaks in the body fluid and all will cause catastrophic consequence.In addition, synthetic polymer can't provide the optimum chemical environment of tissue regeneration and reconstruction, the support bone conductibility deficiency of formation, and new osteogenesis speed is not ideal enough.Therefore, be badly in need of the natural polymerization objects system of research and development safety non-toxic, as with the natural performed polymer of water as solvent and nontoxic cross-linking agent such as fat diacid acid anhydride and oxidized list, two and the polysaccharide system.
Successful polymer support should be simulated the function of natural tissues extracellular matrix, makes the cell can be in its surface adhesion, normal growth and functional expression.Organic substance in the osteocyte epimatrix mainly is the type i collagen fiber, account for more than 90% of organic principle, all the other are aminopolysaccharide, noncollagen protein, peptide class and lipid, comprising multiple specific biological active substance (as bone morphogenetic protein ((bone morphogenetic proteins, BMP) etc., inorganic matter mainly is a hydroxyapatite.
Collagen is used to bone tissue engineering stent material very early, its advantage is: excellent biological compatibility, form the aminoacid of collagen and easily discerned by cell receptor, in vivo easily by the Collagenase enzymolysis, the regeneration and the reconstruction that can be bone provide physical support and best chemical environment; Shortcoming is: intensity a little less than, the figuration ability costs an arm and a leg.Therefore need to carry out enhancement process to improve the comprcssive strength of support, be beneficial to the Stress Transfer in the bone process of reconstruction by chemical crosslinking and composite inorganic material.Gelatin is the product of collagen after acid or alkali treatment, has excellent biological compatibility, and in the water soluble, price is cheap more many than collagen, is more suitable for as injectable tissue engineering bracket in the body.Alginate is a kind of natural polysaccharide of separating from Brown algae, because of having excellent biological compatibility and the cheap fields such as food, medicine and organizational project that are widely used in.Olivier Gauthier etc. think hydroxyapatite (hydroxyapatite, HA) and bata-tricalcium phosphate (β-tricalcium phosphate, the coupling of β-TCP) is used separately than pure HA or β-TCP better biological activity.
Summary of the invention
The object of the present invention is to provide a kind of injection aquagel that contains the sodium alginate cross-linking gelatin of biphase calcium phosphor granule.This injection aquagel material easy operating, plastotype reduce wound conveniently, to greatest extent, reduce operating difficulty, reduce patient's misery, reduce risk of infection, cicatrization and medical expense.
Another object of the present invention is to provide a kind of preparation method of injection aquagel of the sodium alginate cross-linking gelatin that contains biphase calcium phosphor granule, this preparation method technology is simple, be easy to control.
The injection aquagel that the present invention also aims to provide a kind of sodium alginate cross-linking gelatin that contains biphase calcium phosphor granule is as the application in the repairing bone defect material.
A kind of injection aquagel that contains the sodium alginate cross-linking gelatin of biphase calcium phosphor granule provided by the invention, by many aldehyde radicals sodium alginate, gelatin, biphase calcium phosphor granule is that feedstock production forms, and wherein the weight proportion of each raw material is many aldehyde radicals sodium alginate 5～20%, gelatin 10～30%, biphase calcium phosphor granule 50～70%.
The preparation method of the injection aquagel of a kind of sodium alginate cross-linking gelatin that contains biphase calcium phosphor granule provided by the invention comprises the steps:
A. under the room temperature with sodium alginate by dispersed with stirring in ethanol, make it become the suspension that concentration is 100～200g/L;
B. sodium metaperiodate is added in the distilled water, lucifuge stirs under the room temperature, make its solution that becomes homogeneous or supersaturated solution, the ratio of the molal quantity of control sodium metaperiodate and the molal quantity of sodium alginate monomeric unit is between 1: 10～9: 10, and the volume of distilled water equates with alcoholic acid volume among the step a;
C. solution among the step b is poured in the suspension of the step a in the stirring, lucifuge is reacted to degree of oxidation and is reached predetermined value;
D. after treating that degree of oxidation reaches predetermined value, add with initially the equimolar ethylene glycol of sodium metaperiodate is in reactant liquor, lucifuge continues to stir with cessation reaction;
E. with 1～10 times of ethanol sodium alginate is precipitated out, filters drying to the reactant liquor volume, the dissolving of gained precipitation adding distil water is filtered, and filtrate is transferred to bag filter, dialyse in the distilled water, when the dialysis medium at the absorbance at λ=223nm place 0～0.01 the time, stop to dialyse;
F. take out the solution in the bag filter, lyophilization can obtain many aldehyde radicals of solid sodium alginate;
G. many aldehyde radicals sodium alginate being dissolved in 0～0.1M Borax/PBS buffer, to obtain concentration be 5%～30% A liquid;
H. gelatin is dissolved in 35～40 ℃ the hot water and obtains 10%～20% solution, add biphase calcium phosphor granule again and fully mix and obtain B liquid;
I. A liquid and B liquid are respectively charged into mix in the bitubular fibrin glue syringe of tool spiral mixing test tube after, the amino reaction rapidly of aldehyde radical on the sodium alginate strand and the end on the gelatin, in 3～15min, make gelatin be cross-linked to form tridimensional network, obtain containing the injection aquagel of the sodium alginate cross-linking gelatin of biphase calcium phosphor granule thus.
In the above-mentioned preparation method, the described degree of oxidation of step c can calculate by the concentration of remaining sodium metaperiodate in the iodometry assaying reaction liquid, wherein molal quantity * 100% of total monomeric unit of the molal quantity/sodium alginate of the monomeric unit of the sodium alginate of degree of oxidation (%)=oxidized; Mixed active cell, bioactive molecule or medicine wait and strengthen therapeutic effect as required in the described B liquid of step h.
The injection aquagel of the sodium alginate cross-linking gelatin that contains biphase calcium phosphor granule of the present invention's preparation, has excellent biocompatibility, intensity preferably, can be used as injection type degradable bone tissue engineering scaffold, be used for the treatment of the damaged or bone quantity not sufficient of the bone that causes by multiple diseases such as tumor, wound, severe infections, congenital malformations.
The injection aquagel that contains the sodium alginate cross-linking gelatin of biphase calcium phosphor granule provided by the invention is a kind of injection aquagel that comprises inorganic/organic facies, its key component comprises organic facies: the gelatin hydrogel of many aldehyde radicals sodium alginate cross-linking, they come from natural, safety non-toxic, excellent biological compatibility, biological degradability are arranged, there is the signal of cell recognition in the surface, and the regeneration and the reconstruction that can be bone provide physical support and best chemical environment.Use macromole and make cross-linking agent, form network structure and can greatly improve mechanical property.Contain a certain amount of moisture in the gel, be beneficial to the diffusion of nutrient substance and refuse.Inorganic wild phase is a biphase calcium phosphor granule, the inorganic constituents basically identical of its composition and body bone tissue, and have osteoinductive and certain bone conductibility.Compared with prior art, the present invention has following characteristics:
(1) material is the pure natural polymeric system of safety non-toxic.Many aldehyde radicals sodium alginate is that the natural polysaccharide, the gelatin that come from Sargassum are the protein that comes from animal collagen, be safety non-toxic natural component.With the sodium alginate is cross-linking agent, has overcome medium and small molecule crosslinked dose toxicity and the safety issue of material in the past.
(2) regeneration and the reconstruction for bone provides best physicochemical environment.Inorganic calcium phosphorus uniform particles is embedded in the porous three-dimensional network of sodium alginate covalent cross-linking gelatin, the extracellular matrix components of having simulated natural bone tissue makes material have excellent biocompatibility and adjustable physical and mechanical properties, biodegradability.
(3) syringeability of material.Advantage is: the bone that can fill Any shape is damaged, can contact closely with surrounding tissue.Easy operating, plastotype reduce wound conveniently, to greatest extent, reduce operating difficulty, reduce patient's misery, reduce risk of infection, cicatrization and medical expense.And owing to be liquid when not using, can follow the curing of reinjecting behind the uniform mixing such as competent cell, bioactive molecule, medicine.
The specific embodiment
To be easier to understand the present invention with reference to the following example, and provide embodiment and be in order to illustrate the present invention, rather than in order to limit the scope of the invention.
Embodiment 1
The sodium alginate of 50.00g is scattered in is made into suspension (I) in the 250ml dehydrated alcohol, the sodium metaperiodate of 21.50g is dissolved in wiring solution-forming in the 250ml water (II).(II) added in (I), and lucifuge is taken out 2 parts of 5ml reactant liquors behind stirring at room 6h on the magnetic stirring apparatus, analyze its degree of oxidation.Add 5.64mL ethylene glycol in the residual reaction liquid immediately, lucifuge stirring reaction 15min, slowly pouring in the 500mL dehydrated alcohol that vigorous stirring separates out sodium alginate again, filter, gained is deposited in 40 ℃ of vacuum drying 12h, reuse dissolved in distilled water (concentration is 200g/L), and 4 ℃ leave standstill 1h, filter, filtrate dialyse to UV spectrophotometer measuring less than NaIO in the dialysis medium
4Have (λ=223nm), a lyophilizing.The degree of oxidation of this reaction is 39.77%.
Many aldehyde radicals of 1.00g sodium alginate is added 10mL 0.1M Borax/PBS solution (pH=9.4), and 37 ℃ of following stirrings are made into uniform solution (A liquid).The 1.50g gelatin is dissolved under 37 ℃ in the distilled water of 10ml and becomes uniform solution, add the 2.50g biphase calcium phosphor granule again, fully mix B liquid.Under 37 ℃, A liquid and B liquid are mixed, form gel in the 8min.
Embodiment 2
The sodium alginate of 50.00g is scattered in is made into suspension (I) in the 250ml dehydrated alcohol, the sodium metaperiodate of 32.40g is dissolved in wiring solution-forming in the 250ml water (II).(II) added in (I), and lucifuge is taken out 2 parts of 5ml reactant liquors behind stirring at room 6h on the magnetic stirring apparatus, analyze its degree of oxidation.Add 8.47mL ethylene glycol in the residual reaction liquid immediately, lucifuge stirring reaction 15min, slowly pouring in the 500mL dehydrated alcohol that vigorous stirring separates out sodium alginate again, filter, gained is deposited in 40 ℃ of vacuum drying 12h, reuse dissolved in distilled water (concentration is 200g/L), and 4 ℃ leave standstill 1h, filter, filtrate dialyse to UV spectrophotometer measuring less than NaIO in the dialysis medium
4Have (λ=223nm), a lyophilizing.The degree of oxidation of this reaction is 58.82%.
Many aldehyde radicals of 1.00g sodium alginate is added 10mL 0.1M Borax/PBS solution (pH=9.4), and 37 ℃ of following stirrings are made into uniform solution (A liquid).The 1.50g gelatin is dissolved under 37 ℃ in the distilled water of 10ml and becomes uniform solution, add the 2.50g biphase calcium phosphor granule again, fully mix B liquid.Under 37 ℃, A liquid and B liquid are mixed, form gel in the 6min.
Embodiment 3
The sodium alginate of 50.00g is scattered in is made into suspension (I) in the 250ml dehydrated alcohol, the sodium metaperiodate of 43.20g is dissolved in wiring solution-forming in the 250ml water (II).(II) added in (I), and lucifuge is taken out 2 parts of 5ml reactant liquors behind stirring at room 6h on the magnetic stirring apparatus, analyze its degree of oxidation.Add 11.28mL ethylene glycol in the residual reaction liquid immediately, lucifuge stirring reaction 15min, slowly pouring in the 500mL dehydrated alcohol that vigorous stirring separates out sodium alginate again, filter, gained is deposited in 40 ℃ of vacuum drying 12h, reuse dissolved in distilled water (concentration is 200g/L), and 4 ℃ leave standstill 1h, filter, filtrate dialyse to UV spectrophotometer measuring less than NaIO in the dialysis medium
4Have (λ=223nm), a lyophilizing.The degree of oxidation of this reaction is 79.20%.
Many aldehyde radicals of 1.00g sodium alginate is added 10mL 0.1M Borax/PBS solution (pH=9.4), and 37 ℃ of following stirrings are made into uniform solution (A solution).The 1.50g gelatin is dissolved under 37 ℃ in the distilled water of 10ml and becomes uniform solution, add the 2.50g biphase calcium phosphor granule again, fully mix B liquid.Under 37 ℃, A liquid and B liquid are mixed, form gel in the 5min.
Embodiment 4
The sodium alginate of 50.00g is scattered in is made into suspension (I) in the 250ml dehydrated alcohol, the sodium metaperiodate of 53.99g is dissolved in wiring solution-forming in the 250ml water (II).(II) added in (I), and lucifuge is taken out 2 parts of 5ml reactant liquors behind stirring at room 6h on the magnetic stirring apparatus, analyze its degree of oxidation.Add 14.10mL ethylene glycol in the residual reaction liquid immediately, lucifuge stirring reaction 15min, slowly pouring in the 500mL dehydrated alcohol that vigorous stirring separates out sodium alginate again, filter, gained is deposited in 40 ℃ of vacuum drying 12h, reuse dissolved in distilled water (concentration is 200g/L), and 4 ℃ leave standstill 1h, filter, filtrate dialyse to UV spectrophotometer measuring less than NaIO in the dialysis medium
4Have (λ=223nm), a lyophilizing.The degree of oxidation of this reaction is 89.21%.
Many aldehyde radicals of 1.00g sodium alginate is added 10mL 0.1M Borax/PBS solution (pH=9.4), and 37 ℃ of following stirrings are made into uniform solution (A liquid).The 1.50g gelatin is dissolved under 37 ℃ in the distilled water of 10ml and becomes uniform solution, add the 2.50g biphase calcium phosphor granule again, fully mix B liquid.Under 37 ℃, A liquid and B liquid are mixed, form gel in the 3min.
Embodiment 5
The sodium alginate of 50.00g is scattered in is made into suspension (I) in the 250ml dehydrated alcohol, the sodium metaperiodate of 43.20g is dissolved in wiring solution-forming in the 250ml water (II).(II) added in (I), and lucifuge is taken out 2 parts of 5ml reactant liquors behind stirring at room 6h on the magnetic stirring apparatus, analyze its degree of oxidation.Add 11.28mL ethylene glycol in the residual reaction liquid immediately, lucifuge stirring reaction 15min, slowly pouring in the 500mL dehydrated alcohol that vigorous stirring separates out sodium alginate again, filter, gained is deposited in 40 ℃ of vacuum drying 12h, reuse dissolved in distilled water (concentration is 200g/L), and 4 ℃ leave standstill 1h, filter, filtrate dialyse to UV spectrophotometer measuring less than NaIO in the dialysis medium
4Have (λ=223nm), a lyophilizing.The degree of oxidation of this reaction is 79.20%.
Many aldehyde radicals of 1.00g sodium alginate is added 10mL PBS buffer, 37 ℃, be made into uniform solution (A liquid) under stirring.The 1.50g gelatin is dissolved under 37 ℃ in the distilled water of 10ml and becomes uniform solution, add the 2.50g biphase calcium phosphor granule again, fully mix B liquid.Under 37 ℃, A liquid and B liquid are mixed, form gel in the 15min.
Embodiment 6
The sodium alginate of 50.00g is scattered in is made into suspension (I) in the 250ml dehydrated alcohol, the sodium metaperiodate of 10.80g is dissolved in wiring solution-forming in the 250ml water (II).(II) added in (I), and lucifuge is taken out 2 parts of 5ml reactant liquors behind stirring at room 6h on the magnetic stirring apparatus, analyze its degree of oxidation.Add 2.82mL ethylene glycol in the residual reaction liquid immediately, lucifuge stirring reaction 15min, slowly pouring in the 500mL dehydrated alcohol that vigorous stirring separates out sodium alginate again, filter, gained is deposited in 40 ℃ of vacuum drying 12h, reuse dissolved in distilled water (concentration is 200g/L), and 4 ℃ leave standstill 1h, filter, filtrate dialyse to UV spectrophotometer measuring less than NaIO in the dialysis medium
4Have (λ=223nm), a lyophilizing.The degree of oxidation of this reaction is 20.00%.
Many aldehyde radicals of 1.00g sodium alginate is added 10mL 0.05M Borax/PBS solution (pH=9.4), and 37 ℃ of following stirrings are made into uniform solution (A liquid).The 1.50g gelatin is dissolved under 37 ℃ in the distilled water of 10ml and becomes uniform solution, add the 2.50g biphase calcium phosphor granule again, fully mix B liquid.Under 37 ℃, A liquid and B liquid are mixed, form gel in the 10min.
Claims (6)
1. an injection aquagel that contains the sodium alginate cross-linking gelatin of biphase calcium phosphor granule is characterized in that by many aldehyde radicals sodium alginate, gelatin, biphase calcium phosphor granule being that feedstock production forms.
2. the injection aquagel that contains the sodium alginate cross-linking gelatin of biphase calcium phosphor granule according to claim 1, the weight proportion that it is characterized in that described raw material are many aldehyde radicals sodium alginate 5～20%, gelatin 10～30%, biphase calcium phosphor granule 50～70%.
3. the preparation method of the injection aquagel of claim 1 or the 2 described sodium alginate cross-linking gelatins that contain biphase calcium phosphor granule comprises the steps:
A. under the room temperature with sodium alginate by dispersed with stirring in ethanol, make it become the suspension that concentration is 100～200g/L;
B. sodium metaperiodate is added in the distilled water, lucifuge stirs under the room temperature, make its solution that becomes homogeneous or supersaturated solution, the ratio of the molal quantity of control sodium metaperiodate and the molal quantity of sodium alginate monomeric unit is between 1: 10～9: 10, and the volume of distilled water equates with alcoholic acid volume among the step a;
C. solution among the step b is poured in the suspension of the step a in the stirring, lucifuge is reacted to degree of oxidation and is reached predetermined value;
D. after treating that degree of oxidation reaches predetermined value, add with initially the equimolar ethylene glycol of sodium metaperiodate is in reactant liquor, lucifuge continues to stir with cessation reaction;
E. with 1～10 times of ethanol sodium alginate is precipitated out, filters drying to the reactant liquor volume, the dissolving of gained precipitation adding distil water is filtered, and filtrate is transferred to bag filter, dialyse in the distilled water, when the dialysis medium at the absorbance at λ=223nm place 0～0.01 the time, stop to dialyse;
F. take out the solution in the bag filter, lyophilization can obtain many aldehyde radicals of solid sodium alginate;
G. many aldehyde radicals sodium alginate being dissolved in 0～0.1M Borax/PBS buffer, to obtain concentration be 5%～30% A liquid;
H. gelatin is dissolved in 35～40 ℃ the hot water and obtains 10%～20% solution, add biphase calcium phosphor granule again and fully mix and obtain B liquid;
I. A liquid and B liquid are respectively charged into mix in the bitubular fibrin glue syringe of tool spiral mixing test tube after, the amino reaction rapidly of aldehyde radical on the sodium alginate strand and the end on the gelatin, in 3～15min, make gelatin be cross-linked to form tridimensional network, obtain containing the injection aquagel of the sodium alginate cross-linking gelatin of biphase calcium phosphor granule thus.
4. the preparation method of the injection aquagel of the sodium alginate cross-linking gelatin that contains biphase calcium phosphor granule according to claim 3, it is characterized in that the described degree of oxidation of step c can calculate by the concentration of remaining sodium metaperiodate in the iodometry assaying reaction liquid, wherein molal quantity * 100% of total monomeric unit of the molal quantity/sodium alginate of the monomeric unit of the sodium alginate of degree of oxidation (%)=oxidized.
5. the preparation method of the injection aquagel of the sodium alginate cross-linking gelatin that contains biphase calcium phosphor granule according to claim 3 is characterized in that being mixed with competent cell, bioactive molecule or medicine in the described B liquid of step h.
6. the injection aquagel of claim 1 or the 2 described sodium alginate cross-linking gelatins that contain biphase calcium phosphor granule is as the application in the material of repairing bone defect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100368428A CN100408112C (en) | 2006-07-31 | 2006-07-31 | Injectable hydrogel of sodium alginate cross-linked gelatin containing biphasic calcium-phosphorus particles and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100368428A CN100408112C (en) | 2006-07-31 | 2006-07-31 | Injectable hydrogel of sodium alginate cross-linked gelatin containing biphasic calcium-phosphorus particles and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1907504A true CN1907504A (en) | 2007-02-07 |
| CN100408112C CN100408112C (en) | 2008-08-06 |
Family
ID=37698841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100368428A Expired - Fee Related CN100408112C (en) | 2006-07-31 | 2006-07-31 | Injectable hydrogel of sodium alginate cross-linked gelatin containing biphasic calcium-phosphorus particles and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100408112C (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101570582B (en) * | 2009-05-26 | 2011-07-20 | 中山大学附属第一医院 | Electroactive polymer with water solubility and biodegradability as well as preparation method and application thereof |
| CN102250365A (en) * | 2011-05-09 | 2011-11-23 | 武汉理工大学 | PH-sensitive reduction responsive nanogel and preparation method thereof |
| CN102351957A (en) * | 2011-08-18 | 2012-02-15 | 西南交通大学 | Oxidation method of natural polymeric amylose with high oxidisability |
| CN102417734A (en) * | 2011-11-21 | 2012-04-18 | 东华大学 | Oxidized sodium alginate/gelatin degradable hydrogel and preparation method thereof |
| CN106310383A (en) * | 2016-10-18 | 2017-01-11 | 郑伟 | Injectable bone repair hydrogel and preparation method thereof |
| CN106693067A (en) * | 2016-07-15 | 2017-05-24 | 温州生物材料与工程研究所 | Preparation of self-healing and template-free porous scaffold |
| CN106821772A (en) * | 2017-03-06 | 2017-06-13 | 广东石油化工学院 | A kind of preparation method of network interpenetrating face mask substrate material |
| CN108855014A (en) * | 2018-08-05 | 2018-11-23 | 广州小众环保科技有限公司 | A kind of heavy metal absorbent and the preparation method and application thereof |
| CN108926737A (en) * | 2018-07-05 | 2018-12-04 | 爱美客技术发展股份有限公司 | A kind of medical sealing system, preparation method and its usage |
| CN110548171A (en) * | 2019-06-25 | 2019-12-10 | 苏州大学附属第一医院 | Gelatin-based bone tissue adhesive, and preparation method and application thereof |
| CN111166941A (en) * | 2020-01-17 | 2020-05-19 | 上海贝奥路生物材料有限公司 | Tissue defect repairing agent and preparation method and using method thereof |
| CN111588916A (en) * | 2020-06-03 | 2020-08-28 | 中国人民解放军陆军军医大学第二附属医院 | A kind of injectable hydrogel, preparation method and use thereof |
| CN111803697A (en) * | 2020-07-16 | 2020-10-23 | 太原理工大学 | A kind of preparation method of drug-loaded sodium alginate/gelatin composite hydrogel type Band-Aid |
| CN114957726A (en) * | 2022-06-22 | 2022-08-30 | 陕西科技大学 | Nano-cellulose reinforced sodium alginate hydrogel and preparation method and application thereof |
| CN116019975A (en) * | 2023-01-06 | 2023-04-28 | 天津市天津医院 | An injectable hydrogel loaded with anti-inflammatory factor 4-octyl itaconate and its preparation method and application |
| CN116139332A (en) * | 2023-03-06 | 2023-05-23 | 合肥工业大学 | Low-heat-release antibacterial and anti-inflammatory injectable bone cement and preparation method thereof |
| CN116251235A (en) * | 2022-12-14 | 2023-06-13 | 中国人民解放军空军军医大学 | Porous osteoconductive/inducible self-curing calcium phosphate composite material and its preparation method |
| CN117413748A (en) * | 2023-10-23 | 2024-01-19 | 中奥生态环境股份有限公司 | A kind of facade greening using straw modular fiber soil |
| CN117695443A (en) * | 2024-02-05 | 2024-03-15 | 四川大学华西医院 | Negative poisson ratio structured artificial intervertebral disc and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US447812A (en) * | 1891-03-10 | Power-feed sawing-machine | ||
| EP1562630A4 (en) * | 2002-10-31 | 2009-02-18 | Univ Northwestern | INJECTIONABLE BIOADHESIVE POLYMERIC HYDROGELS AND ASSOCIATED METHODS OF ENZYMATIC PREPARATION |
| CN1486753A (en) * | 2003-08-11 | 2004-04-07 | 天津大学 | Preparation method of injectable hydrochloride chitosan/calcium phosphate bone repair material |
| CN1279973C (en) * | 2004-07-22 | 2006-10-18 | 徐放 | Injected gel type bone repairing biological active material and its preparing method |
-
2006
- 2006-07-31 CN CNB2006100368428A patent/CN100408112C/en not_active Expired - Fee Related
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101570582B (en) * | 2009-05-26 | 2011-07-20 | 中山大学附属第一医院 | Electroactive polymer with water solubility and biodegradability as well as preparation method and application thereof |
| CN102250365A (en) * | 2011-05-09 | 2011-11-23 | 武汉理工大学 | PH-sensitive reduction responsive nanogel and preparation method thereof |
| CN102250365B (en) * | 2011-05-09 | 2013-03-20 | 武汉理工大学 | PH-sensitive reduction responsive nanogel and preparation method thereof |
| CN102351957A (en) * | 2011-08-18 | 2012-02-15 | 西南交通大学 | Oxidation method of natural polymeric amylose with high oxidisability |
| CN102417734A (en) * | 2011-11-21 | 2012-04-18 | 东华大学 | Oxidized sodium alginate/gelatin degradable hydrogel and preparation method thereof |
| CN106693067A (en) * | 2016-07-15 | 2017-05-24 | 温州生物材料与工程研究所 | Preparation of self-healing and template-free porous scaffold |
| CN106310383A (en) * | 2016-10-18 | 2017-01-11 | 郑伟 | Injectable bone repair hydrogel and preparation method thereof |
| CN106821772A (en) * | 2017-03-06 | 2017-06-13 | 广东石油化工学院 | A kind of preparation method of network interpenetrating face mask substrate material |
| CN108926737B (en) * | 2018-07-05 | 2021-12-10 | 爱美客技术发展股份有限公司 | Medical sealing system, preparation method and application thereof |
| CN108926737A (en) * | 2018-07-05 | 2018-12-04 | 爱美客技术发展股份有限公司 | A kind of medical sealing system, preparation method and its usage |
| CN108855014B (en) * | 2018-08-05 | 2021-08-13 | 广州小众环保科技有限公司 | Heavy metal adsorbent and preparation method and application thereof |
| CN108855014A (en) * | 2018-08-05 | 2018-11-23 | 广州小众环保科技有限公司 | A kind of heavy metal absorbent and the preparation method and application thereof |
| CN110548171A (en) * | 2019-06-25 | 2019-12-10 | 苏州大学附属第一医院 | Gelatin-based bone tissue adhesive, and preparation method and application thereof |
| CN111166941A (en) * | 2020-01-17 | 2020-05-19 | 上海贝奥路生物材料有限公司 | Tissue defect repairing agent and preparation method and using method thereof |
| CN111588916A (en) * | 2020-06-03 | 2020-08-28 | 中国人民解放军陆军军医大学第二附属医院 | A kind of injectable hydrogel, preparation method and use thereof |
| CN111803697A (en) * | 2020-07-16 | 2020-10-23 | 太原理工大学 | A kind of preparation method of drug-loaded sodium alginate/gelatin composite hydrogel type Band-Aid |
| CN114957726A (en) * | 2022-06-22 | 2022-08-30 | 陕西科技大学 | Nano-cellulose reinforced sodium alginate hydrogel and preparation method and application thereof |
| CN116251235A (en) * | 2022-12-14 | 2023-06-13 | 中国人民解放军空军军医大学 | Porous osteoconductive/inducible self-curing calcium phosphate composite material and its preparation method |
| CN116019975A (en) * | 2023-01-06 | 2023-04-28 | 天津市天津医院 | An injectable hydrogel loaded with anti-inflammatory factor 4-octyl itaconate and its preparation method and application |
| CN116139332A (en) * | 2023-03-06 | 2023-05-23 | 合肥工业大学 | Low-heat-release antibacterial and anti-inflammatory injectable bone cement and preparation method thereof |
| CN117413748A (en) * | 2023-10-23 | 2024-01-19 | 中奥生态环境股份有限公司 | A kind of facade greening using straw modular fiber soil |
| CN117695443A (en) * | 2024-02-05 | 2024-03-15 | 四川大学华西医院 | Negative poisson ratio structured artificial intervertebral disc and preparation method thereof |
| CN117695443B (en) * | 2024-02-05 | 2024-04-30 | 四川大学华西医院 | Negative poisson ratio structured artificial intervertebral disc and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100408112C (en) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1907504A (en) | Injectable hydrogel of sodium alginate crosslinked gelatin containing biphase calcium-phosphorus particles and preparation method and application thereof | |
| KR100894265B1 (en) | Injectable bone regeneration material containing bone formation promoting peptide | |
| Sowmya et al. | Role of nanostructured biopolymers and bioceramics in enamel, dentin and periodontal tissue regeneration | |
| CN106310383B (en) | Injectable bone repair hydrogel and preparation method thereof | |
| Venkatesan et al. | Role of alginate in bone tissue engineering | |
| Kim et al. | Chitosan and its derivatives for tissue engineering applications | |
| CN101301491B (en) | Polyaldehyde-based sodium alginate cross-linked calcium polyphosphate/chitosan composite scaffold and its preparation and application | |
| CN1241657C (en) | Degradable material capable of guiding the regeneration and renovation process of hard tissue and its preparation | |
| JP6851377B2 (en) | Bioactive polymer for bone regeneration | |
| JP2005535736A (en) | Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring | |
| Abdul-Monem et al. | Light-cured hyaluronic acid composite hydrogels using riboflavin as a photoinitiator for bone regeneration applications | |
| Tripathy et al. | Hybrid composite biomaterials | |
| CN100540069C (en) | Biodegradable active medical tissue adhesive and preparation method thereof | |
| Zhang et al. | Incorporation of synthetic water-soluble curcumin polymeric drug within calcium phosphate cements for bone defect repairing | |
| Liu et al. | Applications of bacterial cellulose-based composite materials in hard tissue regenerative medicine | |
| CN102989041A (en) | Chitin fiber reinforced collagen base bone tissue engineering scaffold with compounded human mesenchymal stem cells and preparation method | |
| CN111973797B (en) | Non-invasive implantation high-viscosity adhesive material for orthopedics department and preparation method and application thereof | |
| AU2007200685A1 (en) | Granulate-Matrix | |
| Essawy et al. | Biocompatible chitosan in unique applications for tissue engineering | |
| ES2688324T3 (en) | Self-hardening bioactive cement compositions with partially deacetylated chitin as bone graft substituents | |
| Mohanraj | Plant-derived resorbable polymers in tissue engineering | |
| CN1158109C (en) | Biologically cmposite artificial bone and its preparing process | |
| da Silva Oliveira | Development of an Injectable Modified Calcium Phosphate (Bonelike)-Dextrin Hydrogel Biomaterial for Bone Regenaration | |
| Sukpaita | Chitosan/biphasic calcium phosphate composite scaffold incorporated with trichostatin a for bone regeneration | |
| Ivan et al. | Recent Trends in the Design of Biocompatible Gels for Tissue Engineering and Drug Delivery Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080806 Termination date: 20100731 |